Dermatitis Atopic Clinical Trial
Official title:
A Real-World Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Patients Receiving Dupilumab Therapy, With Atopic Dermatitis Control Tool in Gulf Countries
Primary objective: To assess the disease control of moderate to severe atopic dermatitis in patients aged 12 years and above treated with dupilumab therapy using Atopic Dermatitis Control Tool (ADCT) after 24 weeks of treatment. Secondary objectives: - To figure the proportion of patients with reduction of ADCT score by 5 points after 4, 12, and 24 weeks of treatment. - To figure the proportion of patients with ADCT score less than 7 at weeks 4, 12, and 24. - Assess the effectiveness of dupilumab in moderate to severe atopic dermatitis (AD) patients, using the severity score as routine practice SCORing Atopic Dermatitis (SCORAD). - To describe comorbidities related to type 2 inflammation. - To characterize the safety profile of dupilumab in the local Gulf population. - To evaluate treatment satisfaction in the local Gulf population.
24 weeks ;
| NCT number | NCT05214326 |
| Study type | Observational |
| Source | Sanofi |
| Contact | Trial Transparency email recommended (Toll free for US & Canada) |
| Phone | 800-633-1610 |
| [email protected] | |
| Status | Recruiting |
| Phase | |
| Start date | January 18, 2022 |
| Completion date | May 31, 2023 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04135560 -
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT03992417 -
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
|
||
| Active, not recruiting |
NCT04718870 -
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
|
Phase 4 | |
| Recruiting |
NCT05235724 -
A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
|
||
| Recruiting |
NCT05492578 -
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Active, not recruiting |
NCT03687359 -
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
|
||
| Completed |
NCT04823130 -
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
|
Phase 4 | |
| Active, not recruiting |
NCT03849716 -
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
|